Capricor Therapeutics, Inc. (CAPR)
| Market Cap | 243.23M -34.9% |
| Revenue (ttm) | n/a |
| Net Income | -114.59M |
| EPS | -2.32 |
| Shares Out | 57.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,166,955 |
| Open | 3.775 |
| Previous Close | 3.850 |
| Day's Range | 3.658 - 4.200 |
| 52-Week Range | 2.960 - 40.370 |
| Beta | 0.58 |
| Analysts | Hold |
| Price Target | 34.40 (+719.05%) |
| Earnings Date | Aug 6, 2026 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CAPR stock is "Hold." The 12-month stock price target is $34.4, which is an increase of 719.05% from the latest price.
News
CAPR Investigation Notice: Capricor Therapeutics Hit with Securities Fraud Investigation over Clinical Data Misrepresentations – Investors Urged to Contact BFA Law
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fr...
Capricor Therapeutics price target lowered to $5 from $10 at B. Riley
B. Riley lowered the firm’s price target on Capricor Therapeutics (CAPR) to $5 from $10 and keeps a Neutral rating on the shares. The deramiocel AdCom outcome materially reduces approval…
Capricor Therapeutics downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded Capricor Therapeutics (CAPR) to Hold from Buy without a price target after an FDA advisory committee voted nine to three against deramiocel. The firm cites the negative vote,…
Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) (...
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
SAN DIEGO--(BUSINESS WIRE)-- #CAPR--Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors viol...
CAPR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Capricor
Capricor investors lost 60% to 70% after FDA briefing documents raised significant concerns regarding Deramiocel, following earlier Company statements that the FDA had not identified material review i...
Capricor: FDA committee voted evidence did not support Deramiocel effectiveness
Capricor Therapeutics (CAPR) announced that the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectivene...
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ...
Capricor Therapeutics downgraded to Hold from Buy at Maxim
Maxim downgraded Capricor Therapeutics (CAPR) to Hold from Buy.
Capricor Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Capricor Therapeutics (CAPR) to Perform from Outperform. The firm comes away from the July 29 Food and Drug Administration advisory committee meeting with a dim outlook on deram...
Capricor plummets after FDA panel votes against Duchenne heart disease therapy
Shares of Capricor Therapeutics fell nearly 60% in premarket trading on Thursday after the U.S. FDA's panel of experts voted against the effectiveness data of its cell therapy for a heart condition r...
Capricor Therapeutics downgraded to Neutral from Buy at Ladenburg
Ladenburg analyst Rick Bienkowski downgraded Capricor Therapeutics (CAPR) to Neutral from Buy without a price target following the negative FDA panel vote. The firm sees “not much hope” for the…
Capricor downgraded to Neutral at Cantor with ‘unlikely’ path forward
Cantor Fitzgerald analyst Kristen Kluska downgraded Capricor Therapeutics (CAPR) to Neutral from Overweight with a price target of $3.50, down from $62. An FDA advisory committee voted against deramio...
Capricor Therapeutics resumes trading, shares sink 55% to $2.99
07:15 EDT Capricor Therapeutics (CAPR) resumes trading, shares sink 55% to $2.99
Capricor Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis downgraded Capricor Therapeutics (CAPR) to Neutral from Buy without a price target The firm views the 9-3 negative FDA panel vote against deramiocel as placing...
Capricor Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Capricor Therapeutics (CAPR) to Neutral from Overweight with a price target of $2, down from $58. An FDA advisory panel voted 3 to 9 on the question…
FDA panel votes 9-3 against Capricor’s deramiocel
An FDA panel voted against the benefits of Capricor Therapeutics (CAPR)’ treatment for cardiomyopathy in Duchenne muscular dystrophy, deramiocel. The panel voted 9 to 3 against the drug. Published fir...
Capricor downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Capricor Therapeutics (CAPR) to Neutral from Overweight with a price target of $3.50, down from $62.
FDA panel votes against Capricor's Duchenne heart disease therapy
The U.S. FDA's panel of independent advisers on Wednesday voted against the benefits of Capricor Therapeutics' cell therapy, deramiocel, for treating cardiomyopathy in Duchenne muscular dystrophy, a...
Capricor Therapeutics announces publication of HOPE-3 data on deramiocel
Capricor Therapeutics (CAPR) announced that The Lancet has published results from the Company’s pivotal Phase 3 HOPE-3 clinical trial evaluating Deramiocel, its investigational cell therapy for the tr...
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy
--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Pri...
Capricor Therapeutics downgraded to Neutral from Buy at Alliance Global
Alliance Global downgraded Capricor Therapeutics (CAPR) to Neutral from Buy with a price target of $7, down from $51. The upcoming deramiocel FDA panel looks like an uphill battle based…
Capricor Therapeutics downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded Capricor Therapeutics (CAPR) to Neutral from Buy with a price target of $7, down from $38, after the FDA issued its briefing documents ahead of the advisory…
B. Riley downgrades Capricor as FDA briefing docs ‘incompatible with approval’
As previously reported, B. Riley analyst Madison El-Saadi downgraded Capricor Therapeutics (CAPR) to Neutral from Buy with a price target of $10, down from $63, following the release of the…
Capricor says analyses in FDA’s briefing materials ‘rely on’ SAP version 1.1
Capricor Therapeutics (CAPR) provided an update ahead of the Company’s upcoming FDA Advisory Committee meeting, at which an independent advisory committee will discuss Capricor’s Biologics License App...